

## OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## **Product datasheet for BP2052**

## Apolipoprotein A I / APO AI Rabbit Polyclonal Antibody

## **Product data:**

Product Type:	Primary Antibodies
Applications:	ID, Ie, RID, WB
Recommended Dilution:	Radial Immunodiffusion. Immuno Double-Diffusion. Rocket IEP. Western blot (Immunoblotting).
Reactivity:	Mouse
Host:	Rabbit
Clonality:	Polyclonal
Immunogen:	Purified Mouse Apolipoprotein Al from mouse plasma high density lipoprotein.
Specificity:	This antibody is specific for Mouse Apolipoprotein A1 (Apo A1). Extremely low recognition of Human Apo A1.
Formulation:	State: Serum State: Liquid Neat Serum (heat inactivated and 0.22µm filtered) Preservative: 0.025% Sodium Azide
Concentration:	lot specific
Conjugation:	Unconjugated
Storage:	Upon receipt, store (in aliquots) at -20°C to -80°C. Avoid repeated freezing and thawing.
Stability:	Shelf life: one year from despatch.
Gene Name:	apolipoprotein A-I
Database Link:	Entrez Gene 11806 Mouse Q00623



This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2022 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US

	Apolipoprotein A I / APO AI Rabbit Polyclonal Antibody – BP2052
Background:	Apolipoprotein A I promotes cholesterol efflux from tissues to the liver for excretion. Apolipoprotein A I is the major protein component of high density lipoprotein (HDL) in the plasma. Synthesized in the liver and small intestine, it consists of two identical chains of 77 amino acids; an 18 amino acid signal peptide is removed co-translationally and a 6 amino acid propeptide is cleaved post-translationally. Apolipoprotein A I is a cofactor for lecithin cholesterolacyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. Defects in the Apolipoprotein A I gene are associated with HDL deficiency and Tangier disease.
	The therapeutic potential of apoA-I has been recently assessed in patients with acute coronary syndromes, using a recombinant form of a naturally occurring variant of apoA-I. The availability of recombinant normal apoA-I should facilitate further investigation into the potential usefulness of apoA-I in preventing atherosclerotic vascular diseases.
Synonyms:	APOA1, ApoA-I, Apo-AI, ApoAI

This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2022 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US